Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

228
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
228
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

981
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
981
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

222
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
222

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Viscoelastic Tool Highlighting Severity-Dependent Platelet Dysfunction in Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Atherosclerosis and dementia - causal aspects and preventive potential.

Atherosclerosis·2026
Same author

Managing Coagulation Abnormalities, Bleeding, and Thrombosis in Patients with Cirrhosis.

Journal of general internal medicine·2026
Same author

Discrepancies of results for post infusion levels of extended half-life factor VIII/IX concentrates - a cause of concern, awaiting for solution.

Clinical chemistry and laboratory medicine·2026
Same author

Measurement uncertainty of ISO 17511:2020 compliant and globally standardized PT/INR test results.

Research and practice in thrombosis and haemostasis·2026
Same author

Characterization of allogeneic platelet gel from adult donor blood and umbilical cord blood activated with locally prepared cryoprecipitate and thrombin: A pilot exercise.

Transfusion·2026

Related Experiment Video

Updated: Dec 28, 2025

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.1K

Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review.

Katrine Laura Rasmussen1, Malou Philips1, Armando Tripodi2

  • 1Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.

European Journal of Haematology
|February 13, 2020
PubMed
Summary

Interpreting an isolated prolonged activated partial thromboplastin time (APTT) requires a diagnostic strategy. This review outlines causes and presents an algorithm to differentiate lupus anticoagulants from rare factor deficiencies.

Keywords:
activated partial thromboplastin timehemophilialupus anticoagulants

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.5K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.3K

Related Experiment Videos

Last Updated: Dec 28, 2025

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.1K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.5K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.3K

Area of Science:

  • Clinical Chemistry
  • Hematology
  • Diagnostic Laboratory Medicine

Background:

  • An isolated prolonged activated partial thromboplastin time (APTT) with normal prothrombin time (PT) or international normalized ratio (INR) is a common laboratory finding.
  • This unexpected result necessitates further investigation to guide patient management and diagnostic strategies.
  • The APTT test, originally developed for hemophilia monitoring, exhibits variable sensitivity to different coagulation factor deficiencies.

Purpose of the Study:

  • To summarize the potential causes of an isolated prolonged APTT.
  • To present a diagnostic algorithm for differentiating between lupus anticoagulants and factor deficiencies.
  • To emphasize the clinical importance of identifying the cause of prolonged APTT for appropriate therapeutic follow-up.

Main Methods:

  • Review of literature on causes of isolated prolonged APTT.
  • Development of a diagnostic algorithm to distinguish between lupus anticoagulants and factor deficiencies.
  • Analysis of common and rare causes based on clinical presentation and laboratory findings.

Main Results:

  • Isolated prolonged APTT can be attributed to lupus anticoagulants, heparin therapy, or specific coagulation factor deficiencies.
  • Lupus anticoagulants are a common cause, while factor deficiencies are rare.
  • The proposed algorithm aids in distinguishing between these causes.

Conclusions:

  • Accurate interpretation of an isolated prolonged APTT is crucial for patient care.
  • A systematic diagnostic approach can effectively differentiate between lupus anticoagulants and factor deficiencies.
  • Identifying the underlying cause ensures correct therapeutic management and prevents unnecessary surgical delays.